Tucotuzumab celmoleukin
Tucotuzumab celmoleukin
Tucotuzumab celmoleukin (pronunciation: too-koh-TOO-zoo-mab sel-moh-LOO-kin) is a biopharmaceutical drug used in the treatment of certain types of cancer. It is a monoclonal antibody that has been engineered to stimulate the body's immune system to attack cancer cells.
Etymology
The name "Tucotuzumab celmoleukin" is derived from the International Nonproprietary Name (INN) system for pharmaceutical substances. "Tucotuzumab" indicates that it is a monoclonal antibody (mab) used for neoplastic diseases (tuzumab). "Celmoleukin" is a term used to describe a molecule that has been engineered to include a cytokine, in this case, interleukin-2 (IL-2).
Mechanism of Action
Tucotuzumab celmoleukin works by binding to the EGFR on the surface of cancer cells. This binding triggers an immune response that leads to the destruction of the cancer cells. The addition of the IL-2 molecule enhances this immune response, making the drug more effective.
Related Terms
- Monoclonal Antibodies
- Biopharmaceuticals
- Epidermal Growth Factor Receptor
- Interleukin-2
- International Nonproprietary Names
External links
- Medical encyclopedia article on Tucotuzumab celmoleukin
- Wikipedia's article - Tucotuzumab celmoleukin
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski